Gene Therapy with HSV1-sr39TK/GCV Exhibits a Stronger Therapeutic Efficacy Than HSV1-TK/GCV in Rat C6 Glioma Cells
Figure 7
Hematoxylin and eosin (HE) staining of the xenograft tumor tissues from control group (a), C6-TK group (b), and C6-sr39TK group (c) at day 17 after ganciclovir (GCV) administration (×400). Thin arrow and broad arrow indicated necrotic or hemorrhagic areas in tumors from C6-TK group and, more prominently, the C6-sr39TK group.
